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Background: SR-BI binds HCV E2 glycoprotein and lipoprotein components.
Results:HCV entry exploits several SR-BI properties and different viral and cellular determinants present on the viral particles.
Conclusion: SR-BI is a multifunctional entry factor essential for infectivity of HCV particles with different biophysical proper-
ties and host protein compositions.
Significance: Studying HCV subpopulations reveals differential entry steps and receptor usage.
Hepatitis C virus (HCV) particles assemble along the very low
density lipoprotein pathway and are released from hepatocytes
as entities varying in their degree of lipid and apolipoprotein
(apo) association as well as buoyant densities. Little is known
about the cell entry pathway of these different HCV particle
subpopulations, which likely occurs by regulated spatiotempo-
ral processes involving several cell surface molecules. One of
these molecules is the scavenger receptor BI (SR-BI), a receptor
for high density lipoprotein that can bind to the HCV glycopro-
tein E2. By studying the entry properties of infectious virus sub-
populations differing in their buoyant densities, we show that
these HCV particles utilize SR-BI in a manifold manner. First,
SR-BI mediates primary attachment of HCV particles of inter-
mediate density to cells. These initial interactions involve apo-
lipoproteins, such as apolipoprotein E, present on the surface of
HCVparticles, but not the E2 glycoprotein, suggesting that lipo-
protein components in the virion act as host-derived ligands for
important entry factors such as SR-BI. Second, we found that in
contrast to this initial attachment, SR-BImediates entry ofHCV
particles independent of their buoyant density. This function of
SR-BI does not depend onE2/SR-BI interaction but relies on the
lipid transfer activity of SR-BI, probably by facilitating entry
steps along with other HCV entry co-factors. Finally, our results
underscore a third function of SR-BI governed by specific resi-
dues in hypervariable region 1 of E2 leading to enhanced cell
entry and depending on SR-BI ability to bind to E2.
Withmore than 130million persistently infected individuals
worldwide, hepatitis C virus (HCV)5 has a substantial impact on
public health. HCV infection is characterized by its high pro-
pensity to persist with up to 80% of individuals failing to elimi-
nate the virus. Infected patients have a high risk to develop
severe liver damage such as cirrhosis and hepatocellular carci-
noma with liver transplantation as the final treatment option.
No vaccine against HCV is yet available, and despite the ongo-
ing development of HCV-specific DAAs (direct-acting antivi-
rals) such as protease inhibitors, it remains of utmost impor-
tance to pursue the development of novel DAAs that can target
alternative steps of HCV life cycle to more efficiently cure
HCV-infected individuals. HCV entry into the cell offers
numerous targets for development of such antiviral treatments
(for review, see Ref. 1).
HCV is an enveloped positive-strandedRNAvirus of the Fla-
viviridae family. A hallmark of HCV particles is their peculiar
heterogeneity, exhibiting diverse buoyant densities ranging
from 1.06 to 1.25 g/ml in the blood of infected patients
(2–6). Viral RNA detected in low density fractions is associated
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with lipoprotein components such as triglycerides and apolipo-
proteins (apo) (2, 3, 5). A lipo-viro-particle (LVP) model con-
sisting of HCV core protein, RNA, and E1 and E2 glycoproteins
incrusted into lipoprotein-like structure has been proposed (2,
7). Similar to ex vivo HCV particles, in vitro produced HCV
particles, i.e. cell culture-produced HCV (HCVcc), exhibit a
broad density profile with high specific infectivity associated
with low density fractions (8–15). Additionally, recent evi-
dence suggests that HCVcc particles contain apolipoproteins
on their surface and that their lipid composition resembles that
of low density and very low density lipoproteins (LDLs and
VLDLs, respectively) (16–19). These cellular components
likely influence HCV infectivity (17, 20–23). In line with these
observations, HCV assembly and egress strongly depends on
components of the VLDL synthesis machinery (20–22, 24, 25).
The remarkable property of HCV to associate with lipoprotein
components might affect receptor usage and entry route and
appears to protect HCV fromneutralizing antibodies by shield-
ing of antigenic epitopes (for review, see Ref. 26).
Extensive studies ex vivo using HCV derived from infected
patients (27–29) and in vitro usingHCVmodels (12, 13, 30–34)
suggest that viral entry into hepatocytes, the predominant tar-
get cells, is a complex process involving the viral E1 and E2
envelope glycoproteins and several host cell surface factors.
Attachment of viral particles to the host cell are mediated by
glycosaminoglycans (35, 36) and/or the LDL receptor (17, 27,
29, 37), although it is unclear whether such interactions subse-
quently lead to a productive infection. Then a set of four mole-
cules needs to be concomitantly present on the cell surface to
allow HCV entry, probably after this initial capture. These are
the scavenger receptor BI (SR-BI) (38, 39), CD81 tetraspanin
(40), Claudin-1 (CLDN1) (41), and Occludin (OCLN) (42, 43).
Furthermore, host cell kinases have been shown to regulate
HCV entry by promoting cell entry factor associations (44).
HCV particles are internalized by clathrin-dependent endocy-
tosis (45, 46). Subsequent release of the viral genome into the
cytoplasm is thought to occur after low pH-induced fusion of
the viral and the endosomal membranes, a process that is likely
triggered by the viral envelope glycoproteins and upon their
interaction with CD81 (36, 46–50). Yet, the exact roles of the
HCVentry factors for cell attachment, internalization, and sub-
sequent membrane fusion are still elusive.
The HCV entry factor SR-BI is a “multi-ligand” receptor that
binds different classes of lipoproteins and thereby regulates the
supply of cholesterol to the cell by its bidirectional lipid transfer
function (51, 52). SR-BI was initially proposed as a HCV recep-
tor based on its capacity to mediate binding of soluble HCV E2
glycoprotein (sE2) to human hepatic cells (38). Using cell entry
models, i.e.HCVpseudoparticles (HCVpp) andHCVcc, we and
others demonstrated that SR-BI is essential for viral entry (for
review, see Ref. 26) involving an interplay between SR-BI and
the hypervariable region-1 (HVR1), a 27-amino acid-residue-
long region, located at the N terminus of E2. HCV entry is also
modulated by SR-BI ligands (22, 23, 53–57). It is enhanced by
high density lipoprotein (HDL) in a still poorly defined process
that involves SR-BI lipid transfer function and HVR1 (23,
55–59) and that modulates neutralization efficiency by anti-
bodies (60, 61).
Data obtained with CHO cells expressing theHCV entry fac-
tors suggest that SR-BI, but not CD81 or CLDN1 (41), could
mediate HCVcc attachment to cells. However, results obtained
with experiments analyzing the kinetics of HCV infection indi-
cate that SR-BI also plays a role at a post-binding stage (62).
Thus, the exact function(s) of SR-BI in the entry process of
HCV particles is still enigmatic. Moreover, the impact of lipids
and lipoproteins associated with viral particles on SR-BI-de-
pendent entry has not been studied in detail.
By studyingHCVcc subpopulations separated by density gra-
dient centrifugation, we revealed three different functions of
SR-BI that are essential forHCV cell entry. Taking advantage of
rodent orthologs of SR-BI and HVR1 mutants in this study, we
dissected themodalities bywhich SR-BImediates these distinct
functions.
EXPERIMENTAL PROCEDURES
Cell Lines and Reagents—Human Huh-7 (63), Huh-7.5 (kind
gift of C. Rice), BRL3A rat hepatoma (ATCC CRL-1442), and
293T kidney (ATCC CRL-1573) cells were grown in DMEM
(Invitrogen) supplemented with 10% fetal bovine serum (Invit-
rogen). Fu5AH rat hepatoma cells (64) were grown in Eagle’s
minimal essential medium supplemented with 1% L-glutamine
and 5% newborn calf serum. BLT-4 (65) and human HDL were
purchased from Chembridge and Calbiochem, respectively.
Antibodies—For Western blot analysis, human SR-BI was
detected with CLA-1 mAB (BD Pharmingen), rodent SR-BI
with NB400–104 (Novus), -actin with AC74 (Sigma), and
HCV core with C7–50 (Santa Cruz). For FACS analysis, human
SR-BI was stained with CLA-1, rodent SR-BI with GTX30467
polyAb (Genetex), human CD81 with JS81 mAb (BD Pharmin-
gen), and human CLDN1 with 2H10D10mAb (Zymed Labora-
tories Inc.). The 3/11 (34) and H52 (66) are E2-specific mAbs.
A4 (67) is an E1-specificmAb. Anti-SR-BI antibodies were gen-
erated by genetic immunization and have been described else-
where (62, 68).
Expression Constructs and Establishment of Cell Lines
Expressing CLDN1, OCLN, CD81, and SR-BI wt/Mutants—
Retroviral vectors expressing human CD81 (GenBankTM acces-
sion number: NM_004356), Claudin-1 (NM_021101), and SR-BI
(Z22555) were described previously (58). Rat (NM_031329),
mouse (NM_008756), or human OCLN (NM_002538) and rat
(NM_031541), mouse SR-BI (NM_016741), or human/mouse
chimeric SR-BI cDNAs were inserted in CNCmurine leukemia
virus vector backbones (a kind gift of M. Collins) harboring
selectable marker genes for puromycin and G418, respectively.
Construct details are available upon request. cDNAs encoding
six human/mouse SR-BI chimeras were generated by PCR by
swapping three SR-BI domains between amino acid positions
38–215, 216–398, and 399–432 (primer sequences are avail-
able upon request). Although the HHH and MMM SR-BI con-
structs refer to the wild-type human (H) and mouse (M) SR-BI
molecules, respectively, the human/mouse SR-BI chimeras
were denominated according to the origin of either SR-BI
domain, e.g. HMM bears the domain 1 from human SR-BI and
the domains 2 and 3 from murine SR-BI. cDNAs encoding
mutant mouse SR-BI molecules, M158R and G420H/G424H,
that exhibit reduced lipid transfer properties (69–71)were gen-
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erated. All mutants were sequenced to ensure that the clones
possessed only the expected mutation. Retroviral vectors con-
taining these cDNAs were produced from 293T cells as VSV-
G-pseudotyped particles as described previously (72, 73). Stable
expression of either receptor in target cells was obtained by
transduction with vector particle-containing supernatants of
293T producer cells followed by antibiotic selection.
Down-regulation of SR-BI in Huh-7.5 Cell Line—The down-
regulation of SR-BI in Huh-7.5 cells was achieved using small
interfering RNA (shRNA)-expressing lentiviral vectors (target
sequence GGCACTGTTCTGGAACCTTC) as previously
described (50).
Binding and Cell Surface Staining Assays—Binding of sE2
was performed as previously described (61, 74). Briefly, sE2 har-
boring a His tag was incubated for 1 h at 37 °C with 106 target
cells. The amount of cell-bound sE2 was determined by FACS
analysis using 2 g/ml anti-His antibody (pentaHis, Qiagen)
and using allophycocyanin-conjugated anti-mouse antibodies.
HDL was labeled using Amersham Biosciences Cy5 Mono-
Reactive Dye Pack (GE Healthcare) following the manufactur-
er’s protocol. Unbound Cy5 was removed by applying labeled
HDL on illustra MicroSpin G-25 Columns (GE Healthcare).
Cy5-HDL binding was performed for 1 h at 4 °C on 106 target
cells.
The surface expression of humanCD81, humanCLDN1, and
human or mouse SR-BI was quantified by FACS analysis from
106 live cells using antibodies added to cells for 1 h at 4 °C. After
washing, the binding of antibody to the cell surface was
detected using RPE (R-Phycoerythrin)- or allophycocyanin-
conjugated anti-mouse antibodies.
Lipid Transfer Assays—Lipid efflux assays were performed as
previously described (75). After plating, cells were labeled by
incubation with [3H]cholesterol (1 Ci/ml) for 48 h. Subse-
quently cells were incubated for 24 h in the presence of BSA
(0.5%) and newborn calf serum (25%) for Fu5AHor fetal bovine
serum (25%) for BRL3a to allow equilibration of the label. After
equilibration, cholesterol acceptors (20 g of phospholipid/ml
isolated HDL) were added in serum-free medium and incu-
bated with cells for 4 h at 37 °C. Fractional cholesterol efflux
(expressed as percentage) was calculated as the amount of the
label recovered in themedium divided by the total label in each
well (radioactivity in the medium  radioactivity in the cells)
obtained after lipid extraction from cells in a mixture of 3:2
hexane-isopropyl alcohol (3:2 v/v). The background cholesterol
efflux obtained in the absence of cholesterol acceptor was sub-
tracted from the efflux values obtained with the test samples.
Selective HDL-CE (cholesteryl ester) uptake was performed
as previously described (76). Cells were plated in 24-well tissue
culture plates (105 cells/well). Two days after plating, cells were
washed three times with PBS and once with serum-free
medium. Cells were subsequently incubated in the presence of
[3H]CE-labeledHDL diluted in serum-freemedium at 37 °C for
5 h. At the end of incubation, the medium was removed, and
cells were washed 4 times with PBS and incubated in the pres-
ence of an excess of unlabeled HDL (100 g of protein) for 30
min. Cells were then washed 4 times with PBS and solubilized
with 200l of NaOH0.2 N for 15min at room temperaturewith
gentle mixing. Protein content (20l) from each well was mea-
sured using the bicinchoninic acid protein reagent (Pierce). The
radioactive content of 100 l of each cell lysate was measured
by liquid scintillation counting. Selective uptake was calculated
from the known specific radioactivity of radiolabeled HDL-CE
and is expressed in g of HDL-CE/g of cell protein.
Production of HCVpp and HCVpp Entry Assays—The
expression vectors for the E1E2 glycoproteins of HCV strain
H77 (AF009606), for the HVR1 deletion mutant (G384-
N411), and for the L399R point mutant in HVR1 were
described previously (30, 39, 55). Viral pseudoparticles named
HCVpp and VSV-Gpp harbored the glycoproteins of HCV and
VSV, respectively, and were produced as described previously
(30). Before harvest of viral particle-containing supernatants,
producer cells were incubated inmediumdevoid of serum lipo-
protein (Opti-MEM) for 24 h.
For infection assays, target cells were seeded 24 h before
inoculation. 2 h before infection, target cells were preincubated
in Opti-MEM devoid of serum lipoprotein. Then medium was
removed, and dilutions of viral supernatants were added to the
cells and incubated for 4 h. Where indicated, human serum
(HS), prepared as described previously (55), or human HDL
(Calbiochem)was added to the infection reactions at 6g/ml of
cholesterol. Supernatants were then removed, and the infected
cells were kept in regular medium (DMEM, 10% FCS) for 72 h
before analysis of the percentage of GFP-positive cells by FACS
analysis (30). The infectious titers were expressed as GFP infec-
tion units per ml of HCVpp-containing medium. Background
infection was controlled by using non-enveloped particles.
HCVcc Production and Cell Binding Assays—Plasmid pFK
H77/JFH1/HQL displaying adaptive mutations (Y835H (in
NS2), K1402Q (in NS3), and V2440L (in NS5A)) that enhance
production and infectivity of HCVcc particles (77) was used to
generate recombinant genomes containing the sameH77 HCV
E1E2 sequences, parental or HVR1-modified, used for HCVpp
production. Generation of infectious HCV RNAs, production,
and titration of HCVcc particles from Huh-7.5 cells was per-
formed as previously reported (23, 58, 78).
For cell binding assay, BRL3Acells expressing or not express-
ing the HCV entry factors, seeded in 48-well plates were incu-
bated with HCVcc particles (1 105 HCV RNA copies) for 2 h
as indicated in figure legends. Cells were then washed three
times with PBS, and total RNA from cell lysates was extracted
using the RNeasy Mini kit (Qiagen) and reverse-transcribed
using the iScript cDNA synthesis kit (Bio-Rad). HCV and
housekeeping gene RNA were quantified with HCV (5-CTT-
CACGCAGAAAGCGCCTA and 5-CAAGCGCCCTAT-
CAGGCAGT) or rat GAPDH (5-GTTACCAGGGCTGCCT-
TCTC and 5-GGGTTTCCCGTTGATGACC) using the
FastStart Universal SYBRGreenMaster kit (RocheApplied Sci-
ence) on an Applied StepOne Real-Time PCR apparatus.
Iodixanol Density Gradient Fractionation—HCVcc particle-
containing supernatants were passed through 0.45-m pore-
size filters and concentrated by Vivaspin molecular weight cut-
off 100-kDa columns (Sartorius). 1ml of concentrated particles
was layered on top of a 0–30% continuous iodixanol gradient
(Optiprep, Axis-Shield). Gradients were centrifuged for 16 h at
31,000 rpm in a SW41 TI swinging rotor at 4 °C using an
Optima L-90 K Beckmann centrifuge. Twelve fractions of 1 ml
SR-BI Dependency of HCV Subpopulations
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were collected from the top, subjected to another Vivaspin col-
umn centrifugationmolecular weight cutoff 100 kDa to remove
iodixanol, and then analyzed for virus infectivity, core protein
amounts, viral RNA copy number, and receptor binding
properties.
HCV core protein was quantified using an enzyme-linked
immunosorbent assay (ELISA) according to themanufacturer’s
instructions (Wako Chemicals, Neuss, Germany). Viral RNAs
were isolated from gradient fractions using Tri Reagent solu-
tion (Sigma) as recommended by the manufacturer. Quantifi-
cation of purified RNAs was carried out as described above for
cell binding assays.
Potassium Depletion—Endocytosis was blocked by potas-
sium depletion as previously described (79). Briefly, cells were
washed twice with PBS (PBS, 1 mM MgCl2, 0.1 mM CaCl2)
followed by 1 wash and a short incubation of 5–7 min in hypo-
tonic medium (PBS/H2O (1:3 v/v)). The cells were then
washed 5–8 times in amedium containing 150mMNaCl, 1 mM
MgCl2, 1 mMCaCl2, 20 mMHEPES/KOH, pH 7.4, 0.5% DMSO,
and 0.5% BSA followed by a 30-min incubation in the same
medium. For HCVcc binding assays, HCVcc particles were
added directly to the medium and processed as described
above.
RESULTS
Attachment Properties of HCVcc Subpopulations to SR-BI—
HCVcc has a heterogeneous profile of buoyant density and
association to lipoprotein components (7, 19), which could dif-
ferentially influence cell entry steps including the interaction
with entry factors such as SR-BI. A previous report using
human SR-BI (hSR-BI)- and human CD81 (hCD81)-expressing
CHO cells suggested that hSR-BI but not hCD81 promotes
binding of total HCVcc particles (41). Thus, using the same
procedure (41), we investigated binding to SR-BI expressed in
Huh-7.5-permissive cells of HCVcc subpopulations separated
along their buoyant densities by iodixanol density gradients.
In agreement with recent reports (9, 14, 15, 19), HCVcc par-
ticles hadmore than 65% of their infectivity in fractions of den-
sities of 1.08–1.13 g/ml, i.e. slightly shifted toward lowdensities
as compared with the peak of HCVRNA level (1.10–1.16 g/ml)
(Fig. 1A). In addition, in lower density fractions, i.e. below 1.08
g/ml, substantial amounts of infectious particles were detected,
accounting for about 30%of total infectivity (Fig. 1A).When the
same amounts of HCVcc particles, i.e. 1  105 HCV genome
equivalent (GE) were compared for each density fractions,
we found that HCVcc particle subpopulations had a variable
capacity to bindHuh-7.5 cells, with amaximal binding detected
for HCVcc particles of low density (i.e. 1.02–1.10 g/ml) (Fig.
1B). By modulating SR-BI levels through its overexpression or
down-regulation (Fig. 1E), we found that SR-BI is a rate-limit-
ing factor that preferentially permits the attachment of HCV
particles of intermediate densities (i.e. above 1.10 g/ml; Fig. 1B).
Indeed, SR-BI up-regulation increased by up to 10-fold the
attachment of the latter HCVcc particles, which was competed
by SR-BI blocking antibodies (Fig. 1C), whereas SR-BI down-
regulation reduced their binding (Fig. 1B). Interestingly, up-
regulation and down-regulation of SR-BI positively and nega-
tively correlated, respectively, with the infectivity of HCVcc
(Fig. 1A). This effect was detected whatever the viral particle
density, in contrast to the lack of impact of SR-BI expression
modulation on binding of low density viral particles (Fig. 1B).
Next, to confirm and extend the significance of these results,
we used BRL3A rat hepatocarcinoma cells devoid of endoge-
nous SR-BI (58) that ectopically expressed, or not, hSR-BI to
levels similar to the endogenous levels detected inHuh-7.5 cells
(Fig. 1, E versus G). Similar to the observations made using
Huh-7.5 cells, we found that a maximal binding to parental
BRL3A cells was detected for HCVcc particles of low density
(i.e. 1.02–1.10 g/ml) that allowed recovery of 10–20% of the
input viral particles (105 HCV GE for each density fraction)
(Fig. 1D). Importantly, although less than 1% of the input viral
particles of intermediate densities (i.e. above 1.10 g/ml) could
be recovered after incubation with BRL3A cells, expression of
hSR-BI in these cells increased by 10–50-fold the recovery of
these latterHCVcc particles (Fig. 1D), in agreementwith results
obtainedwithHuh-7.5 cells overexpressing SR-BI (Fig. 1B). SR-
BI-mediated increased recovery of viral particles of intermedi-
ate density was also detected at 4 °C (Fig. 1F) (although less
intensively than at 37 °C), indicating that hSR-BI promotes
binding of virions. Consistently, SR-BI-mediated binding of
intermediate density HCV particles was also detected when
internalization was prevented in SR-BI-expressing BRL3A cells
(Fig. 1H) through intracellular potassium depletion that inhib-
its clathrin-mediated endocytosis (80) and SR-BI internaliza-
tion (79). In contrast, no change of binding profile upon hSR-BI
expression could be detected for HCVcc particles of lower den-
sities (i.e. below 1.10 g/ml).
Thus, altogether, these results indicated that the capacity of
hSR-BI to interact with HCVcc particles specifically depends
on their physicochemical properties and, in a non-exclusive
manner, that binding of low density HCVcc particles is medi-
ated by another cell surface receptor. Yet, SR-BI also seems to
be involved in the infectivity of viral particles of these latter
densities. We, therefore, sought to investigate the nature of the
determinants that modulate HCV/SR-BI interaction.
Study of Density-fractionated HCVcc Reveals That HVR1
Modulates Particle Properties—HCV E2 binding to human
SR-BI depends on the hypervariable region 1 (HVR1) (38, 79), a
27-amino acid-long region at the N terminus of E2. Here, we
identified a conserved residue in HVR1, Leu-399, that upon
leucine-to-arginine mutation completely abolished E2 binding
to SR-BI, like HVR1 deletion (supplemental Fig. 1A). To clarify
the role of HCV E2 in SR-BI-mediated attachment of HCVcc
particles, we sought to study HVR1 modifications, i.e. through
its deletion (HVR1-HCVcc) or L399R mutation (L399R-
HCVcc). We found that whereas supernatant levels of HCV
RNA and core protein were similar for HVR1-mutant and
parental HCVcc (Fig. 2,A andB, left panels), eitherHVR1mod-
ification had effects on HCVcc infectivity with a reduction of
40-fold for HVR1-HCVcc, consistently with previous reports
(14, 81), and 3-fold for L399R-HCVcc (Fig. 2C, left panel).
Then different parameters of HCVcc density subpopulations
of the above-mentioned HVR1 mutants were analyzed (Fig. 2,
right panels). First, we investigated physical particle release of
HCVcc populations separated along their buoyant densities.
Parental HCVcc and HVR1-HCVcc mutants exhibited a major
SR-BI Dependency of HCV Subpopulations
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peak of physical particles sedimenting at densities of 1.10–1.16
g/ml and containing more than 90% of viral RNA and 95% of
core protein (range, 1.5–3.2  108 genome equivalent/ml and
4.1–9.8  105 fmol/ml at the peak density of 1.12–1.13 g/ml)
(Fig. 2, A and B). In line with studies of others (10, 11, 14), viral
particles could also be detected at higher densities (to up to 1.26
g/ml, data not shown) and at lower densities (to up to 1.02 g/ml;
Fig. 2,A and B). Yet,10–60-fold less physical particles could be
detected forHVR1-HCVccascomparedwithparentalHCVcc in
the low density fractions (i.e. 1.02–1.10 g/ml) (Fig. 2, A and B). In
contrast, as compared with parental HCVcc, L399R-HCVcc had
10-fold higher levels of physical particles in fractions with den-
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sities of 1.02–1.05 g/ml but similar amounts in the other fractions
(i.e. 1.05–1.16 g/ml) (Fig. 2, A and B). Altogether, these results
suggested that HVR1 modulates the assembly, stability, and/or
lipoprotein-association of low density particles.
Next, we analyzed the distribution of infectivity of HCVcc
subpopulations for the above-mentioned HVR1 mutants (Fig.
2C, right panel). As for the HVR1-HCVcc particles, virtually
all infectivity was detected in fractions of densities of 1.10–1.16
FIGURE 1. HCVcc particle attachment to SR-BI. A, HCV infectious titers of virus populations separated by using a continuous iodixanol density gradient
centrifugation were determined on human SR-BI-overexpressing (solid line, Huh-SR-BI) or SR-BI-down-regulated (dotted line, Huh-shRNA) Huh-7.5 cells, as
compared with control Huh-7.5 cells (dashed line, Huh-7.5). Results are expressed as focus-forming units/ml and compared with HCV RNA (GE, genome
equivalent) of each virus population (gray line, HCVcc RNA) determined by RT-qPCR. B, shown is attachment of HCVcc subpopulation to human SR-BI-over-
expressing (solid line, Huh-SR-BI) or SR-BI-down-regulated (dotted line, Huh-shRNA) Huh-7.5 cells as compared with control Huh-7.5 cells (dashed line, Huh-7.5).
Equal amounts of fractionated HCVcc particles, i.e. 1 105 HCV GE for each density fractions, were incubated to the cells. The bound HCVcc particles were
assessed by detection of HCV RNA in lysates of virus-incubated cells and normalized to the human GAPDHmRNA levels (mean S.D.; n	 3). C, shown are the
results of blocking of binding of HCVcc particles of intermediate densities (1.12–1.14 g/ml) to human SR-BI-overexpressingHuh-7.5 cells using SR-BI polyclonal
antibodies (preincubation of the cells with 100-fold dilution of anti-SR-BI serum) and compared with control serum. The results of binding inhibition are
displayed as percentage of blocking of binding comparedwith untreated cells. BoundHCV RNAwas quantified as described in B (mean S.D.; n	 2).D, equal
amounts of fractionatedHCVcc particles, corresponding to 1 105HCVGE contained in fractions of densities specified on the x axis, were allowed to attach on
BRL3A cells expressing (dashed line, BRL-hSR-BI) or not (solid line, BRL3A) human SR-BI for 2 h at 37 °C. BoundHCVRNAwas quantified as described in B (mean
S.D.;n	3). E, cell surface expressionof SR-BI in humanSR-BI-overexpressing (dashed line,Huh-SR-BI), SR-BI-down-regulated (dotted line,Huh-shRNA), or control
Huh-7.5 cells (solid line, Huh-7.5) by immunostaining is shown. Staining with secondary antibody only provided the background of fluorescence (gray line,
Huh-7.5 background). F, equal amounts of fractionatedHCVcc particles (1 105 HCVGE per fraction) were allowed to attach on BRL3A cells expressing (dashed
line, BRL-hSR-BI) or not (solid line, BRL3A) human SR-BI for 2h at 4 °C. Bound HCV RNA was quantified as described in B (mean  S.D.; n 	 3). G, cell surface
expressionof SR-BI in BRL3Acells ectopically expressing, or not, humanSR-BI by immunostaining is shown.H, BRL3Acells expressinghumanSR-BIwere treated
(solid line) or not (dashed line) with potassium-depleted medium and subsequently incubated for 2 h at 37 °C with equal amounts of fractionated HCVcc
particles (1 105 HCV GE). Bound HCV RNA was quantified as described in B (mean S.D.; n	 2).
FIGURE 2. Biophysical properties of HCVcc particles. A–C, HCVcc particles harboring wt (HCVcc), HVR1-deleted (HVR1-HCVcc), or L399R-mutated (L399R-
HCVcc) H77-E1E2 glycoproteins were harvested 48 h after transfection of Huh7.5 cells andwere analyzed from filtered cell culture supernatants (left panels) or
after separation of viral subpopulations into 12 fractions by using continuous iodixanol density gradient centrifugation (right panels). HCV RNA GE (genome
equivalent) (A) and HCV core protein (B) amounts contained in each fractionwere determined by qRT-PCR and ELISA, respectively (mean S.D.; n	 3). C, HCV
infectious titers were determined as focus-forming units/ml. In the right panels, values are plotted against the density of the respective fractions. Statistical
analysiswasperformedbyapairedStudent’s t test: *,p0.05; **,p0.005; ***,p0.0005.D, specific infectivity ofwtHCVcc,HVR1-HCVcc, andL399R-HCVcc
was calculated as infectivity per fmol core protein and is presented as percentage of total specific infectivity in individual fractions.
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g/ml (Fig. 2C), containing most physical particles. No infectiv-
ity could be detected in low density fractions, presumably due
to strongly reduced levels of physical particles in these fractions
(Fig. 2, A and B). Nonetheless, this contrasted with the L399R-
HCVcc particles for which80% of the infectivity remained in
these low density fractions (Fig. 2C) and particularly in those of
lowest densities (1.02–1.05 g/ml). Importantly, the L399R-
HCVcc viruses had 5–10-fold reduced infectious titers than the
parental HCVcc particles in the peak infectivity fractions of the
latter virus (p  0.05), i.e. 1.08–1.13 g/ml (Fig. 2C), despite
similar amounts of physical particles in such fractions (Fig. 2,A
and B). Altogether, these results indicated that HVR1 deter-
mines at least in part infectivity and perhaps lipid association of
HCVcc particles. Viruses harboring wt versus L399R-mutated
E2 glycoproteins were then compared in the subsequent exper-
iments to analyze SR-BI involvement in HCV entry.
Intermediate density HCVcc Particles Use SR-BI for Cell
Attachment via Their Lipoprotein Components—We then
sought to determine the importance of E2/SR-BI interaction
in mediating attachment of the different virus populations.
First, we found that, unexpectedly, SR-BI induced attach-
ment of HCVcc particles of intermediate density for both wt
viruses (Figs. 1B and 3A) and modified viruses harboring the
L399R mutation in HVR1 (Fig. 3A) that abrogated soluble
E2/SR-BI binding (supplemental Fig. 1A). Second, no signif-
icant attachment to cells expressing CD81 could be detected
for parental and HVR1-mutated HCVcc particles contained
in all density gradient fractions (Fig. 3D), although individ-
ually, the recombinant HVR1-modified E2 proteins had
higher capacity to bind CD81 than wt E2 (supplemental Fig.
1A). Third, the mouse SR-BI ortholog, which does not allow
binding of HCV E2 (38, 82), also mediated attachment of wt
FIGURE 3. Cell attachment properties of HCVcc particles of different densities. A–D, shown is cell attachment of wt HCVcc and L399R-HCVcc particles to
BRL3A cells expressing human SR-BI (A),mouse SR-BI (B),mouseM158R SR-BImutant (C), or humanCD81 (D). Shown is -fold binding of HCVcc particles to these
cells in comparison to parental BRL3A cells, as assessed by detection in lysates of virus-incubated cells of viral RNA by qRT-PCR that was normalized to the rat
GAPDHmRNA levels. The left panels show the binding of non-fractionated viral particles to BRL3A cells expressing the indicated receptors (mean S.D.; n	
3), whereas the right panels show the binding of viral particles in individual density fractions (results are representative of three independent experiments).
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and L399R-mutated HCVcc intermediate density particles
(Fig. 3B).
Confirming that SR-BI specifically interacts with HCVcc parti-
cles of intermediate densities, we found that SR-BI blocking anti-
bodies almost completely inhibited SR-BI-mediated attachment
of wt and L399R-mutated HCVcc particles to SR-BI-expressing
BRL3A cells (Fig. 4A, left panel). Yet we found that this HCVcc/
SR-BI interaction was not mediated by the HCV E2 glycoprotein
as it was abrogated neither by BLT-4 (Fig. 4B, left panel), a small
molecule SR-BI inhibitor (65), nor by E2-specific antibodies (Fig.
4C, left panel), both of which block sE2 binding to SR-BI (58) (Fig.
4,B andC, insets). Altogether, these results indicated thatHCVE2
is not at play forHCVcc attachment to SR-BI, which thus involves
alternative virus surface component(s).
FIGURE4.BlockingofHCVccbindingand infectivity.A–E, left panels, shownare the results of blockingof bindingofHCVccparticles of intermediatedensities
(1.12–1.14 g/ml) to human SR-BI in the presence of anti-SR-BI or control serum (100-fold dilution) (A) or in the presence of BLT-4 (50 M) or the DMSO diluent
(B) by preincubating viral particles with mAb 3/11 against HCV E2 (20 g/ml) or PBS diluent (C) or by preincubating cells with VLDL (50 g/ml) (D) or purified
apoE (50 g/ml) (E). The results are displayed as the percentage of blocking of binding to hSR-BI-expressing BRL3A cells incubated with the indicated
compounds comparedwithuntreated cells (mean S.D.;n	3). The insets in the left panelsofB andC show the results of blockingof sE2binding toBRL3A cells
expressing hSR-BI or hCD81 with the same concentration of the BLT-4 compound or 3/11 antibody used for blocking of HCVcc binding. A–E, right panels,
neutralizationof infectivityof viral particlesof the indicatedbuoyantdensitieswithanti-SR-BI or control serum (100-folddilution) (A) orwithBLT-4 (50M) (B) by
preincubating viral particles with mAb 3/11 (20 g/ml) (C) or by preincubating cells with VLDL (50 g/ml) (D) or with purified apoE (50 g/ml) (E). The results
of infectivity inhibition are displayed as the percentage of neutralization relative to the infectivity in Huh-7.5 cells determined in the absence of inhibitor. The
results are representative of five independent experiments.
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Previous studies have underscored the association of HCV
particles with -lipoprotein components such as apoB, apoC-I,
or apoE (17, 22, 28), which may contribute to HCV/SR-BI
interaction. Importantly, no attachment of HCVcc particles
occurred to cells expressing the M158R-mutated mouse SR-BI
(Fig. 3C) that does not bind lipoproteins (70, 71) (supplemental
Fig. 4C), suggesting that a lipoprotein component(s) could
influence attachment to SR-BI of HCVcc particles. Consis-
tently, purified VLDL and apoE strongly inhibited attachment
of intermediate density HCVcc particles to SR-BI-expressing
BRL3A cells (Fig. 4, D and E, left panels). Again, strictly analo-
gous results were obtained for HCVcc particles carrying the
L399Rmutation, as compared with wt virus (Fig. 4, left panels),
further indicating that a host factor rather than a viral ligand
mediates attachment of intermediate density HCVcc particles
to SR-BI.
Then we investigated the impact of these latter molecules on
HCVcc infectivity (Fig. 4, right panels). Consistently with the
inhibition of SR-BI-mediated attachment, both purified VLDL
and apoE inhibited entry of HCVcc of intermediate density in a
dose-dependent manner (Fig. 4,D and E, right panels, and sup-
plemental Fig. 2, D and E). In addition, either molecule also
impaired cell entry of the other HCVcc subpopulations (Fig. 4,
D and E, right panels, and supplemental Fig. 2, D and E), sug-
gesting that lipoprotein components also permit attachment
and/or penetration of HCVcc via SR-BI and/or alternative lipo-
protein receptor(s).
SR-BI Mediates Entry of All HCVcc Subpopulations via Its
Lipid Transfer Activity and Independent of E2/SR-BI Bind-
ing—Importantly, we found that SR-BI antibodies blocked
infectivity inHuh-7.5 cells of both parental andHVR1-mutated
HCVcc particles of intermediate density (1.10 g/ml), as
expected due to the SR-BI role in attachment of the latter viral
particles (Figs. 1 and 2). Importantly, these antibodies also
blocked infectivity of low densityHCVcc particles (1.10 g/ml)
(Fig. 4A, right panel, and supplemental Fig. 2A), which do not
attach to SR-BI (Figs. 1 and 2). This confirmed our assumption
(Fig. 1, A and B) that, besides mediating cell attachment, an
additional function of SR-BI, whichwe designated “access func-
tion” (Table 1), allows cell entry of all HCVcc subpopulations in
a manner independent of E2/SR-BI binding and of HCVcc/
SR-BI attachment. Yet, HCV E2-blocking antibodies neutral-
ized infectivity of HCVcc particles of all densities (Fig. 4C, right
panel, and supplemental Fig. 2C), suggesting that the HCV sur-
face glycoproteins mediate cell entry of all HCVcc subpopula-
tions, although they are not involved in HCVcc attachment to
cells. Furthermore, we found that BLT-4, a small inhibitor of
the lipid transfer activity of SR-BI (65) (supplemental Fig. 3),
inhibited HCVcc infectivity of all HCVcc populations (Fig. 4B,
right panel) in amanner correlating to the levels of lipid transfer
inhibition (supplemental Figs. 2B and 3), indicating that the
physiological activity of SR-BI may exert this access function of
SR-BI by other means than bymediating attachment of HCVcc
particles.
Thus, aiming to discriminate the nature of either “attach-
ment” versus “access” SR-BI functions, we took advantage of the
HCVpp assay, which allows the study of entry factors using
receptor-complementation assays (42, 58) independently of the
lipoprotein components associated toHCVcc particles. As pre-
viously described (42, 82), although it does not bind HCV E2
(38, 82) (Fig. 5A), mouse SR-BI fully supported HCVpp entry
with an efficiency similar to human SR-BI as shown here (Fig.
5B) in BRL3A cells co-expressing human CD81, CLDN1, and
endogenous rat Occludin (BRL-hCD81-hCLDN1 cells). Con-
sistently, despite loss of E2/SR-BI binding (Fig. 5A, supplemen-
tal Fig. 1A), L399R-HCVpp depended on SR-BI for entry into
cells as BRL-hCD81-hCLDN1 cells became susceptible only
upon expression of either mouse or human SR-BI (Fig. 5B).
Finally, we found that BLT-4 inhibited HCVpp entry in BRL-
hCD81-hCLDN1 expressing either human or mouse SR-BI by
about 70–90% (similar to the inhibition of HCVpp entry on
Huh-7 cells) (Fig. 5C), in line with the levels of lipid transfer
inhibition achieved by BLT-4 in these cells (Fig. 5C and supple-
mental Fig. 3). Because HCV E2 does not bind mouse SR-BI,
this result indicated that the SR-BI lipid transfer-dependent
function could be involved in its capacity tomediateHCV entry
independently of E2/SR-BI interaction.
To corroborate these results, we performed infection assays
using mutants of mouse SR-BI that are impaired in their lipid
transfer activities (M158R or G420H-424H) (69, 70) (Fig.
5D and supplemental Fig. 4). In BRL-hCD81-hCLDN1 cells
expressing either mouse mutant, we found that the levels of
HCVpp infection were significantly reduced by about 60–80%
as compared with parental mouse SR-BI (Fig. 5D), which cor-
related well with a 3–4-fold decrease in their lipid transfer
function (Fig. 5D and supplemental Fig. 4). Altogether, these
results indicated that the function of SR-BI used during HCV
entry of all HCVcc populations (access function) is HCV E2/
SR-BI binding-independent but requires the lipid transfer
activity of SR-BI.
The Interaction between HCV E2 and SR-BI Triggers a Third
Function of SR-BI That Leads to Enhanced HCV Entry—Thus
far we described two functions of SR-BI important for HCV cell
entry, an attachment function and an access function,which are
both HCV E2/SR-BI binding-independent (Table 1). Then we
wanted to investigate the potential role of HCV E2 binding to
SR-BI. First, when we introduced in HCVcc genome the L399R
mutation in HVR1 that abrogates HCV E2/SR-BI binding, we
found that these HCVcc particles exhibited a decreased sensi-
tivity to neutralization by anti-SR-BI antibodies (Fig. 4A, right
panel, and supplemental Fig. 2A) or by BLT-4 (Fig. 4B, right
panel, and supplemental Fig. 2B), as compared with parental
HCVcc. Second, we observed that these HVR1-mutated HCVcc
particles, compared with wt viruses, had a 5–10-fold decrease of
infectivity for the viral particle populations that corresponded to
TABLE 1
SR-BI functions and determinants required for HCV entry into cells
Function Determinant HCV subpopulation
Attachment VLDL components (apoE) 1.10–1.16 g/ml
E2-independent (intermediate density)
HVR1-independent
Access SR-BI lipid transfer-dependent 1.02–1.16 g/ml
E2/SR-BI binding-independent (low and intermediate
density)HVR1-independent
Enhancement SR-BI lipid transfer-dependent 1.08–1.12 g/ml
E2/SR-BI binding-dependent (lower intermediate
density)HVR1-dependent
HDL component (apoC-I)
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the highest infectivity levels of parental HCVcc (i.e. 1.08–1.13
g/ml) (Fig. 2C) and that contained the highest amounts of E1E2
glycoproteins (supplemental Fig. 5). Altogether, these results sug-
gested the possibility that E2/SR-BI interaction leads to an
enhanced infectivity for HCVcc particles.
Infection enhancement of HCV infectivity has been reported
before by us and others (55–59, 61). Particularly, HDL fromHS
stimulate post binding entry of HCVpp and HCVcc particles in
a manner that is governed by HVR1 and is dependent on the
lipid transfer function of SR-BI. Our results in this report fur-
ther indicate that infection enhancement is likely related to
HCV E2/SR-BI binding, as cell entry of HVR1-HCVppmutants
harboring E2 glycoproteins that do not bind SR-BI (supplemen-
tal Fig. 1A) was not enhanced by HDL or HS (supplemental Fig.
1B). Consistently, HDL enhanced infectivity of wt HCVcc but
not of L399R-HCVcc particles (supplemental Fig. 6). Finally,
although mouse SR-BI expressed in BRL3A cells mediated effi-
cient HDL binding and lipid transfer (supplemental Fig. 4), it
did not allow enhancement of HCV infection in the presence of
HDL or HS, in contrast to human SR-BI (Fig. 6A and supple-
mental Fig. 1B). Interestingly the absence of HDL-mediated
infection enhancement uncovered an inhibitory activity of lipo-
proteins, possibly due to oxidized lipids (53). Altogether, these
results indicated that although rodent and human SR-BI pro-
mote HCV entry through their access function, only human
SR-BI features both capacities to mediate HCV E2 binding and
to induce HCV entry enhancement in the presence of HDL.
To establish the molecular basis of the difference between
the access function of SR-BI and SR-BI/HDL-mediated entry
enhancement, we generated a set of SR-BI chimeras by swap-
ping segments between human and mouse orthologs. Using
SR-BI sequence comparisons as well as structural features pre-
dictions, we delineated three domains in the SR-BI ectodomain,
i.e. between amino acid positions 38 and 215, 216 and 398, and
399 and 432. We then generated six human/mouse SR-BI
chimeras (Fig. 6B) that were readily expressed in BRL3A cells
(Fig. 6C) and fully functional for lipid transfer (Fig. 6D, sup-
plemental Fig. 7). Although they all supported efficient HCVpp
entry upon expression inBRL-hCD81-hCLDN1cells (Fig. 6E) and
displayed full HDL binding capacities (Fig. 6F), only those chime-
ras that harbored the first domain of human SR-BI supported
HCVentryenhancementbyHDLorHS(Fig. 6G).As shown inFig.
6H,we foundthat the firstdomainofhumanSR-BIharboredbind-
ing sites for HCV E2, as only when this domain was present in a
chimeric human/mouse SR-BI molecule could we demonstrate
sE2 binding with an efficiency comparable with that of wt human
SR-BI.Hence, the ability of these chimericmolecules to bindHCV
E2 correlated with their capacity to induce HDL-mediated infec-
tion enhancement. Altogether, these results suggested that HDL-
mediated stimulation requires HCV E2 binding to SR-BI, which
thuscharacterizes this third functionofSR-BI (referred tobelowas
the enhancement function, Table 1), present in human SR-BI and
distinct from the access function detected with either SR-BI
orthologs.
FIGURE5. InhibitionofHCVentrybyblocking lipid transfer activityof SR-BI.A, bindingofHis-tagged solublewt (sE2) or L399R-mutated (L399R-sE2) H77-E2
glycoprotein to BRL3A cells ectopically expressing CD81 or the indicated SR-BI orthologswas detected by flow cytometry. The results are expressed as -fold of
mean fluorescent intensity relative to themean fluorescent intensity (MFI) determined in the absence of sE2 (mean S.D.; n	 3). B, results are shown of HCV
entry assays in Huh-7 cells or in BRL-hCD81-hCLDN1 rat hepatocarcinoma cells ectopically expressing, or not, human or mouse SR-BI (hSR-BI and mSR-BI,
respectively) along with human CD81, human CLDN-1, and endogenous OCLN. Cells were inoculated with HCVpp harboring wt (HCVpp) or L399R-mutated
(L399R-HCVpp) H77-E1E2 glycoproteins, control virus particles harboring VSV-G glycoprotein (VSV-Gpp, diluted 1:100), or no glycoprotein (noENVpp), and
infectivity titers were determined 72 h after inoculation. Results represent average infectious titers, expressed as infectious unit (IU) per ml (mean S.D.; n	
3). C, shown are the results of inhibition of SR-BI-dependent HCVpp entry, cholesterol efflux (using 50 g/ml HDL-PL), and HDL-CE uptake (using 60 g/ml
HDL-PL) in BRL-hCD81-hCLDN1 cells ectopically expressing hSR-BI ormSR-BI as indicated and inHuh-7 cells treatedwith 50Mof BLT-4 relative toDMSO-only,
set at 100% (mean S.D.; n	 3).D, shown are the results of SR-BI-dependent HCVpp entry assays, cholesterol efflux (using 50g/ml HDL-PL), HDL-CE uptake
(using 60g/ml HDL-PL), and Cy5-labeled HDL binding (using 5g/ml HDL) in BRL-CD81-CLDN1 cells ectopically expressingmutatedmouse SR-BI M158R or
G420H/G424H as indicated. Shown are the percentages of inhibition as compared with cells expressing wild-type mouse SR-BI (mean S.D.; n	 3).
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DISCUSSION
Here we show that SR-BI is a multifunctional entry factor
essential for infectivity ofHCVparticles with different biophys-
ical properties and host protein compositions. The analysis of
HCVcc populations separated by density gradient revealed that
during HCV entry, SR-BI exerts both direct and indirect inter-
actions with different components on the viral particles. Thus,
we propose three distinctHCVentry functions for SR-BI (Table
1): a primary attachment function, an access function, and an
enhancement function that, respectively, lead to the capture of
HCV particles from the extracellular milieu, their functional
entry into cells, and the stimulation of their infectivity. Intrigu-
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ingly, we found that although the binding ofHCVE2 to SR-BI is
required for the latter SR-BI function at a post-attachment step
both the attachment and access functions are independent of
HCV E2/SR-BI interaction. Finally, our results highlight a crit-
ical role of HVR1 residues and of SR-BI domain I for E2/SR-BI
binding and, consequently, the implementation of the enhance-
ment function.
SR-BI is amultiligand receptor thatmediates the binding and
lipid transfer from different classes of lipoproteins (51, 52).
Because of their low density, lipid composition, and association
to apolipoproteins, plasma-derivedHCV as well as HCVcc par-
ticles resembleVLDLparticles in the formof lipo-viro-particles
(for review, see Ref. 7) and, as for HCVcc particles retrieved
from our buoyant density gradients, fall in different subpopu-
lations of low (1.10 g/ml), intermediate (1.10–1.16 g/ml) and
high (1.16 g/ml) densities.
It was previously proposed that SR-BI could act as a receptor
of HCV entry through a direct E2/SR-BI interaction (38, 39).
However, here we found that the initial attachment of HCVcc
particles to SR-BI is independent of E2 but, rather, is mediated
by lipoprotein components, such as apoE. Indeed, a pointmuta-
tion of HVR1 leading to complete loss of E2/SR-BI binding did
not interfere with HCVcc/SR-BI attachment. Consistently, we
found that HCVcc capture by SR-BI cannot be inhibited by
E2/SR-BI binding blockers such as E2 antibodies or BLT-4,
which further excludes a role for HCV E2 in the attachment
function of SR-BI. Moreover, no attachment of HCVcc parti-
cles occurred on the lipoprotein binding-deficient M158R
SR-BImutant. The preferential attachment of HCV particles of
intermediate density to SR-BI via a lipoprotein component is in
agreement with the observation that several apolipoproteins
(apoB, -E, -C-I) are predominantly incorporated into HCVcc
particles of intermediate densities (17, 19) and that apoE plays a
crucial role during HCV assembly and infectivity (17, 20–22,
83–86).
Overall, our data are in agreementwith a previous study indi-
cating that the cellular uptake of HCV particles derived from
the plasma of HCV-infected patients can be mediated by SR-BI
through its interaction with lipoprotein components harbored
by the virus (28). Although there may be differences between
HCVcc and patient-derived particles, e.g. in their apolipopro-
tein composition of viral subpopulations of different densities,
as HCVcc-producing hepatocarcinoma cells are impaired at
late steps of VLDL biogenesis and production (7, 87, 88), our
study further extends these previous results (28) and under-
scores the notion that distinct capture molecules are used by
the different HCV subpopulations to induce attachment to tar-
get cells. Although attachment of HCVcc of intermediate den-
sity, particularly, seems to bemediated by SR-BI, we found that
the infectivity of low density HCVcc particles also involves a
VLDL-derived component as it could be competed by VLDL
and/or by purified apoE. This may involve cell attachment of
these latter viral particles tomolecules such as glycosaminogly-
cans (35, 36, 86), lipoprotein lipase (89), and/or LDL receptor
(17, 27, 29, 37) that all bind VLDL.
We found that the access function of SR-BI that mediates
HCV entry into cells is independent of E2/SR-BI binding.
Indeed, entry of HCV particles bearing HVR1 modifications
abrogating sE2/SR-BI binding remained dependent on the
presence of SR-BI. Likewise, mouse SR-BI mediated full HCV
entry as compared with its human counterpart, in agreement
with previous reports (42, 82, 90). Thus, our results indicated
that a SR-BI property other than E2 binding must be at play
during HCV entry.
SR-BI mediates the bidirectional flux of free and esterified
cholesterol between cells and lipoproteins (51, 52). Here we
found that blocking the lipid transfer activity ofmouse SR-BI by
small chemical inhibitors (BLTs) (65) decreased HCVpp entry.
Likewise, point mutants of mouse SR-BI abrogating lipid trans-
fer (69–71) decreased HCVpp entry as compared with wt
mouse SR-BI. Finally, blocking of lipid transfer of human SR-BI
by either anti-SR-BI antibodies or BLT-4 decreased the infec-
tivity of HCVcc particles of the different buoyant densities,
including those of low density that do not initially attach SR-BI.
Although the access function promoted by SR-BI relies on
the lipid transfer activity of SR-BI but does not depend on
E2/SR-BI binding, it does depend on E2/CD81 interaction, as
shown in this report by sensitivity to antibodies that block
E2/CD81 interaction. This is in line with recent studies reveal-
ing that, whether or not SR-BI bears HCV E2 binding capacity,
HCV entry remains dependent on human CD81 (as well as on
Occludin and Claudin-1) (42, 58). A possibility is that the lipid
transfer function of SR-BI facilitates the formation of an HCV
receptor complex, perhaps by augmenting the rate of recruit-
FIGURE 6. HCV entry into cells expressing human/mouse SR-BI chimeras. A, HCV entry assays using H77-HCVpp (produced in serum-free medium) in the
presence of 6g/ml cholesterol-HDL or 2.5% human ormouse serum and BRL3A cells expressing human ormouse SR-BI alongwith human CD81 and human
CLDN1. Huh-7 cells were used as a reference. Results show the -fold increases of infection determined by calculating the ratios between average infectious
titers determined in the presence or absence (–) of HDL or serum (mean S.D.; n	 3). No changes of infectivity of VSV-Gpp control particles were detected
under these experimental conditions (data not shown). B, a schematic representation of human/mouse SR-BI chimeras shows the three domains that were
swapped between amino acid positions 38 and 215, 216 and 398, and 399 and 432. The gray boxes represent mouse sequences, whereas the white boxes
represent the human sequences. Thedashed boxes represent the SR-BI trans-membranedomains.M, mouse;H, human.C, shown is a comparisonof expression
levels of human/mouse SR-BI chimeras by Western blot analysis using SRBI (400–104) or human SR-BI-specific (CLA-1 mAb) antibodies. Actin staining (AC74
mAb) was used as loading control. D, shown are the results of SR-BI-dependent free cholesterol efflux (using 50 g/ml HDL-PL) and HDL-CE uptake (using 60
g/ml HDL-PL) in BRL3A cells expressingwild-type or chimeric human/mouse SR-BI relative to parental BRL3A (mean S.D.; n	 3). E, shown are the results of
HCV entry assays into BRL-hCD81-hCLDN1 cells ectopically expressing parental human or mouse SR-BI or chimeric human/mouse SR-BI molecules by using
H77-HCVpp, VSV-Gpp (500-fold dilution inmedium), or non-enveloped particles (noENVpp). Results represent average infectious titers, expressed as infection
units/ml (mean S.D.; n	 3). F, shown is binding of Cy5-labeledHDL (using 5g/ml HDL) to BRL3A cells expressing parental or chimeric human/mouse SR-BI.
Results are expressedas -foldofMFI relative to theMFI determined in the absenceofCy5-labeledHDL (meanS.D.;n	3).G, shownareHCVentry assays using
H77-HCVpp in the presence of 6g/ml cholesterol-HDL or 2.5%HS. Results show the -fold increases of infection determined by calculating the ratios between
average infectious titersmeasured in the presence or absence of HDL or HS (mean S.D.; n	 3). No changes of infectivitywith VSV-Gpp control particleswere
detected under these experimental conditions (data not shown). H, shown are results of binding of His-tagged soluble H77-E2 (sE2) to BRL3A cells ectopically
expressing the indicated SR-BI orthologs or chimeras or to cells expressing human CD81 as compared with parental cells. Results are expressed as -fold MFI
relative to the MFI determined in the absence of sE2 (mean S.D.; n	 3).
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ment of the CD81 tetraspanin and the other entry co-factors at
virion-binding sites and/or the internalization of HCV/CD81
complexes via the modulation of the “tetraspanin web,” which
is regulated by cholesterol (91). In this respect it is interesting
that CD81 and SR-BI function cooperatively to initiate HCV
infection (62, 92) and that HCV entry is dependent on mem-
brane cholesterol (92). In contrast to the attachment and access
functions of SR-BI, which both are independent of E2/SR-BI
interaction, E2 binding to SR-BI triggers a third entry function
of SR-BI at a post-attachment step that leads to stimulation of
cell entry (enhancement function).
Compared with HVR1-mutated viruses, whose E2 glycopro-
teins do not bind SR-BI, wt HCVcc particles of all densities
exhibited a higher sensitivity to lipid transfer inhibitors (e.g.
SR-BI antibodies and BLTs), which could be interpreted as a
higher SR-BI dependence for entry. Thus, these results indi-
cated a role for E2/SR-BI interaction for the entry process at a
post-binding step. Consistently, as compared with the HVR1-
mutated viruses, we found that wt HCVcc displayed a10-fold
higher infectivity for HCVcc particles of intermediate density
that exhibited the highest infectivity (1.08–1.13 g/ml) and that
contained the highest levels of E1E2 glycoproteins. Hence, for
HCVcc of both low and intermediate densities, the interplay
between SR-BI, E2, and/orHVR1 seems to trigger an important
SR-BI function leading to enhanced cell entry.
Previous studies revealed that HCVpp entry is specifically
enhanced by HDL in amanner dependent on SR-BI lipid trans-
fer function (55, 56, 58, 60, 61). Here, by studying human/
mouse SR-BI chimeras and their HCV entry properties, we
found that HDL-mediated HCV infection enhancement corre-
lates to E2/SR-BI binding, which itself is modulated by specific
HVR1 residues. The close vicinity of HCV particle and a spe-
cific lipid transfer activity adjacent to the cell entry site could
stimulate infectivity by different manners. Cholesterol transfer
from SR-BI-bound lipo-viro-particles or lipoproteins could be
important to facilitate post-attachment events at the site of
entry into cells. Local enhanced membrane fluidity due to an
elevated cholesterol/lipid content could favor crucial HCV cell
entry events such as receptor movements (93) and interactions
(68, 94), particle internalization (61, 95), and finally fusion with
the host membrane (23, 47, 96). Furthermore, acceleration or
facilitation of these crucial entry steps might help the virus to
escape the host humoral immune response (60, 61) and to
establish persistence (26).
In conclusion, we demonstrate that SR-BI is an entry factor
with unparalleled functions. Its usage by HCV subpopulations
to enter the cell is manifold and, intriguingly, involves different
components on the viral particle (Table 1). First, we show that
the initial attachment of HCV particles is independent of E2
and, at least for particles of intermediate densities, occurs via
SR-BI. The nature of the attachment factor forHCVparticles of
low density was not identified in this study but is likely a mole-
cule that binds VLDL, as deduced from VLDL and apoE com-
petition in infection assays. Thus, in agreement with several
previous studies (17, 22, 84), lipoprotein components provide
the viral particle mimics of host-derived ligands for important
capture molecules such as, e.g. LDL receptor and SR-BI. By
targeting these explicit cholesterol receptors, HCVmight opti-
mize replication in vivo as they are abundantly expressed on
hepatocytes, which themselves harbor the VLDL assembly
machinery that is important for HCV particle production. Sec-
ond, besidesmediating attachment, SR-BI induces entry and/or
entry enhancement of HCV particles. We surmise that,
whether they were initially captured by SR-BI or by alternative
attachment molecules, the viral particles could be “passed on”
to the next entry step, which would allow HCV E2 to directly
interact with CD81 and/or SR-BI in an entry complex poten-
tially containing the other entry co-factors. Why such direct
interactions cannot be detected during the primary attachment
step of the viral particles remains unclear; yet, one possibility is
that modifications of HCV particles occur during/after their
capture on lipoprotein receptor(s), allowing HCV E1E2 to
become accessible for further interactions with CD81 and
SR-BI. AlthoughHCVE2/CD81 interaction was recently found
to prime HCV for low pH-dependent fusion (49), direct inter-
actions between HCV E2 and SR-BI enhance infectivity of the
particle at post-attachment levels (26).
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LEGENDS TO SUPPLEMENTAL FIGURES 
  
Supplemental Fig. 1. Cell entry competence of HVR1-mutants. A, Results of dose-dependent 
binding of His-tagged wild-type H77-E2 soluble glycoprotein (sE2), HVR1-deleted sE2 (ΔHVR1-sE2) 
or sE2 containing the L399R mutation in HVR1 (L399R-sE2) to parental BRL3A cells (top panel) or 
to BRL3A cells expressing human SR-BI (+ hSR-BI) or human CD81 (+ hCD81) (lower panels, as 
indicated). Results of binding for 1 hr at 37°C, detected by flow cytometry using anti-His antibody 
(pentaHis, Qiagen) and allophycocyanine (APC)-conjugated anti-mouse antibodies, are expressed as 
fold MFI (mean fluorescent intensity) relative to the MFI determined in the absence of sE2 
(mean±SD; n=3). B, HCV entry assays using HCVpp harboring wt H77-E1E2 (HCVpp), HVR1-
deleted H77-E1E2 (∆HVR1-HCVpp) or L399R-mutated H77-E1E2 glycoproteins (L399R-HCVpp). 
BRL-hCD81-hCLDN1 cells ectopically expressing human SR-BI (BRL-hCD81-hCLDN1-hSR-BI 
cells) or mouse SR-BI (BRL-hCD81-hCLDN1-mSR-BI cells) or Huh-7 cells were incubated with 
HCVpp in the presence of 6µg/ml cholesterol-HDL or 2.5% human serum (HS) and cell entry was 
measured 72 hr after inoculation. Results show the fold increases of infection as expressed by 
calculating the ratios between average infectious titers determined in the presence vs. absence of HDL 
or HS (mean±SD; n=3).  
 
Supplemental Fig. 2. Dose-response inhibition of HCVcc cell entry. A-E, results of neutralization 
of infectivity of HCVcc harboring wt H77-E1E2 (left panels) and L399R-mutated H77-E1E2 
glycoproteins (right panels) of the indicated buoyant densities. A, neutralization by anti-SR-BI relative 
to control serum (100-, 500 and 1000-fold dilution). B, neutralization by BLT-4 (50, 10 and 1 µM) 
relative to the DMSO diluent. C, neutralization by pre-incubating viral particles with mAb 3/11 
against HCV E2 (20, 4 and 2 µg/ml) relative to pre-incubation with PBS diluent. D-E, neutralization 
by pre-incubating cells with D, VLDL (50, 10 and 1 µg/ml) or with E, purified apoE (50, 10 and 1 
µg/ml) relative to pre-incubation with BSA. The results of infectivity inhibition are displayed as 
- 2 - 
percentage of neutralization relative to the infectivity in Huh-7.5 cells determined in the absence of 
inhibitor. 
 
Supplemental Fig. 3. Inhibition of SR-BI-mediated lipid transfer by BLT-4. Dose-response curves 
for cholesterol efflux (solid line), using 50 µg/ml HDL-PL, and HDL-cholesteryl ester (CE) uptake 
(dashed line), using 60 µg/ml HDL-PL, and cell viability (grey dotted line), using a MTT cell 
proliferation assay (Sigma-Aldrich) on Huh-7, BRL-hCD81-hCLDN1 and BRL-hCD81-hCLDN1 
cells ectopically expressing human SR-BI (BRL-hCD81-hCLDN1-hSR-BI cells) or mouse SR-BI 
(BRL-hCD81-hCLDN1-mSR-BI cells), treated with increasing concentrations of BLT-4, as specified 
on the x-axis (mean±SD; n=3). 
 
Supplemental Fig. 4. Lipid transfer induced by mouse SR-BI mutants. Dose-response curves for 
A, cholesterol efflux, B, HDL-cholesteryl ester (CE) uptake, and C, Cy5-labelled HDL binding 
(mean±SD; n=3) using Fu5AH rat hepatoma cells and BRL3A cells ectopically expressing, or not, the 
indicated SR-BI mutants (mean±SD; n=3). Cells were treated with increasing concentrations of HDL-
PL (phospholipid) or total HDL, as specified on the x-axis. 
 
Supplemental Fig. 5. Detection of viral proteins of fractionated HCVcc particles by western blot 
analysis. Viral proteins present in equal volumes of fractionated HCVcc particles harboring wt 
(HCVcc) or L399R-mutated (L399R-HCVcc) were detected using antibodies directed against H77 E1 
(A4 mAb), H77 E2 (H52 mAb) and HCV core (C7-50 mAb). 
 
Supplemental Fig. 6. Infection-enhancement of fractionated HCVcc particles. Huh7.5 cell entry 
assays using fractionated HCVcc particles harboring wt (HCVcc) or L399R-mutated (L399R-HCVcc) 
H77-E1E2 glycoproteins produced in serum-free medium, in the presence, or not, of 6µg/ml 
cholesterol-HDL. Results show the fold increases of infection determined by calculating the ratios 
between infectious titers determined in the presence or absence of HDL. The results are representative 
of three independent experiments.  
 
Supplemental Fig. 7. Lipid transfer induced by human/mouse SR-BI chimera. Dose-response 
curves for A, cholesterol efflux and B, HDL-cholesteryl ester (CE) uptake (mean±SD; n=3) using 
BRL3A expressing, or not, parental or chimeric human/mouse SR-BI (mean±SD; n=3). Cells were 
treated with increasing concentrations of HDL-PL (phospholipid), as specified on the x-axis. 
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